WS #1009
The data window reveals a dominant signal of positive U.S.-China trade developments, with multiple breaking alerts from Reuters and jetstream.bsky.priority corroborating that Chinese Trade Negotiator Li announced reaching preliminary consensus, agreeing on stable trade relations, and discussing tariff suspensions and mechanisms. This represents a significant de-escalation in trade tensions, potentially overriding earlier bearish signals from Trump's tariff rhetoric and a delayed Trump-Xi meeting. Concurrently, AI infrastructure momentum accelerates with Meta's $12 billion deal with Nebius and Micron's expansion of DRAM/HBM production in Taiwan, signaling continued investment in semiconductor and cloud capabilities. In corporate news, Baxter International's CFO departure and reaffirmed lower-than-expected FY2026 EPS guidance introduce uncertainty for the medtech sector, while several biotech and energy stocks show sharp moves on specific catalysts like clinical trial results and oil pipeline approvals. Geopolitical risks persist with a Russian strike in Ukraine, but these appear secondary to the trade optimism driving broad market gains.
Key developments
- U.S. and China Reach Preliminary Trade Consensus, Discuss Tariff Suspensions
- Meta Signs $12 Billion AI Cloud Deal with Nebius Using NVIDIA Chips
- Micron Expands DRAM/HBM Production in Taiwan After Acquiring PSMC Site
- Baxter International Reaffirms FY2026 EPS Guidance Below Estimates, CFO Departs
- Structure Therapeutics Reports Positive Phase 2 Obesity Drug Data
- Russian Strike Hits Ukraine's Sumy, Wounding Civilians